Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE versus ETHOSUXIMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE versus ETHOSUXIMIDE.
DEPAKOTE vs ETHOSUXIMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Ethosuximide reduces the frequency of spike-and-wave discharges in absence seizures by blocking T-type calcium channels in thalamic neurons, thereby stabilizing neuronal membrane and preventing rhythmic burst firing.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
Adults: 500 mg orally twice daily initially, increase by 250 mg every 4-7 days as needed; maintenance dose 1-2 g/day divided into 2-4 doses. Maximum 1.5 g/dose or 3 g/day.
None Documented
None Documented
Clinical Note
moderateEthosuximide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Fluconazole
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
Terminal elimination half-life is approximately 60 hours (range 40–60 hours) in adults; children may have shorter half-life (~30–40 hours). Long half-life allows once- or twice-daily dosing.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Primarily renal excretion; ~20% as unchanged ethosuximide and ~50% as conjugated metabolite (glucuronide plus minor hydroxymetabolites). Less than 5% eliminated via feces.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Ethosuximide."